“We have seen remarkable results from clinical trials using AAV vectors for AADC gene transfer,” says Shin-ichi Muramatsu, a pioneer of AAV vector research, and a professor in Jichi Medical ...

The FDA granted accelerated approval to eladocagene exuparvovec (Kebilidi) to treat children and adults with aromatic L-amino acid decarboxylase (AADC) deficiency, the agency announced Thursday.

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

Medscape Neurology, March 15, 2010 AADC Gene Therapy for Parkinson's Disease In this video blog, Dr. Kapil D. Sethi discusses a recent study exploring the efficacy, safety, and tolerability of ...

Expert Rev Neurother. 2013;13(6):695-705. Gene therapy using neurotrophic factors is the most promising disease-modifying approach for Parkinson's disease. The strong safety profile and rapidly ...